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Abstract
Background: Chronic obstructive pulmonary disease (COPD) accounts for 10–12 % of primary care consultations,
7 % of hospital admissions and 35 % of chronic incapacity related to productivity. The misuse of inhalers is a
significant problem in COPD because it is associated with reduced therapeutic drug effects leading to lack of
control of both symptoms and disease. Despite all advice, health care professionals’ practice management of
inhalation treatments is usually deficient. Interventions to improve inhaler technique by health care professionals
are limited, especially among primary care professionals, who provide the most care to patients with COPD. The
aim of this study is to evaluate the efficacy of an educational intervention to train general practitioners (GPs) in
the right inhalation technique for the most commonly used inhalers.
Methods/design: We are conducting a pragmatic cluster randomised controlled trial. The sample population is
composed of 267 patients diagnosed with COPD using inhalation therapy selected from among those in 20
general practices, divided into two groups (control and intervention) by block randomisation at 8 primary care
centres. The sample has two levels. The first level is patients with COPD who agree to participate in the trial and
receive the educational intervention from their GPs. The second level is GPs who are primary health care professionals
and receive the educational intervention. The intervention is one session of the educational intervention with a
monitor given to GPs for training in the right inhalation technique. The primary outcome is correct inhalation
technique in patients. Secondary outcomes are functional status (spirometry) and quality of life. The follow-up
period will be 1 year. GPs will have two visits (baseline and at the 1-year follow-up visit. Patients will have four
visits (at baseline and 3, 6 and 12 months). Analysis will be done on an intention-to-treat basis.
Discussion: We carried out three previous clinical trials in patients with COPD, which showed the efficacy of an
educational intervention based on monitor training to improve the inhalation technique in patients. This intervention is
suitable and feasible in the context of clinical practice. Now we are seeking to know if we can improve it when the
monitor is the GP (the real care provider in daily practise).
Trial registration: ISRCTN Registry identifier ISRCTN93725230. Registered on 18 August 2014.
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Background
Chronic obstructive pulmonary disease (COPD) accounts
for 10–12 % of primary care consultations, 35–40 % of
hospital consultations, 7 % of hospital admissions and
35 % of disability related to productivity [1]. The disease
cost represents 2 % of the annual budget of the Ministry
of Health and Consumer Affairs in Spain [1], and in the
European Union the total costs of respiratory disease are
estimated to be about 6 % of the total health budget; 56 %
of this cost is due to COPD [2]. Two thousand euros per
year has been estimated as the mean direct cost generated
by these patients. The major part (43.8 %) corresponds to
hospital admissions, followed by controlled drug con-
sumption (40.8 %) in patients with mild COPD. This per-
centage decreases to 37.4 % and 28.4 % in patients with
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stages III and IV, respectively [3].
The administration of drugs using inhalation tech-
nologies has changed the treatment of respiratory dis-
eases. These drugs have advantages over systemic
therapy, including faster delivery to the targeted organ
and reduction of side effects [4]. The effectiveness of
inhaled drugs can be influenced by numerous factors,
which are mainly age, sex, education level, years of
diagnosis, type of inhaler, use of the right inhalation
technique or use of different devices [5, 6].
The misuse of inhalers is a significant problem in
asthma and COPD because it is associated with reduced
therapeutic drug effects leading to a lack of control both
symptoms and disease [7–10]. If patients are prescribed
a treatment without proper training, a less than optimal
therapeutic effect results [10, 11].
Even though clinical practice guidelines advocate the
implementation of health education programmes during
medical follow-up, in some studies researchers have ob-
served that more than 85 % of patients do not correctly
use their inhalers [11–14]. The educational interventions
proposed by these guidelines must include aspects such
as positive reinforcement, smoking cessation advice, diet
and exercise information, adherence to the therapeutic
regimen and verification of the right inhalation tech-
nique [15, 16].
International guidelines on the management of COPD
refer to the following aspects related to the inhalation
technique [2, 17, 18]. (1) The effectiveness of the bron-
chodilator therapy should be assessed on the basis of not
only the pulmonary capacity of the patient but also other
aspects, such as improvement of symptoms, improve-
ment in daily activities, capacity to perform exercise and
self-control of the symptoms. (2) Most of the patients,
independently of age, can learn to use the proper inhal-
ation technique with appropriate training. (3) Once the
patient has shown the ability to perform the right inhal-
ation technique, the device should be prescribed. (4)
The patient’s ability to use devices must be checked
regularly by highly trained health care professionals, and,
if necessary, the patient must be retrained in the proper
inhalation technique.
Despite these recommendations, the use of inhaler de-
vices by health care professionals is deficient [10, 19]. In-
terventions to improve inhalation technique in health
care professionals are limited, especially among primary
health care professionals, who provide care to most pa-
tients with COPD [19, 20].
Study aims
Our research group has studied the management of
chronic illness in primary care for more than 15 years,
focusing mainly on COPD. The first step taken was to
carry out trials to develop tools to assess therapeutic ad-
herence and educational interventions to improve adher-
ence. Our first educational intervention was designed
with three components (motivational and cognitive as-
pects, as well as skill development in inhalation tech-
niques). The intervention was evaluated in a randomised
controlled trial which showed that treatment adherence
improved by 48 % (relative risk) with a number needed
to treat (NNT) of 6.37 [14]. In the last 3 years, our clin-
ical trials have been focused on the evaluation of educa-
tional interventions to improve inhalation techniques in
patients with COPD. We have designed two educational
interventions to improve inhalation technique: (1) only
written information (leaflet) or (2) written information
(leaflet) reinforced by instructor training. These trials
showed that an intervention with a demonstration by a
trainer is significantly more effective than an informative
leaflet alone, with an increase in the number of patients
who develop proper inhalation technique by 48 % at
3 months and by 41 % at 1-year follow-up [21].
The next step is the start-up of an intervention fo-
cused on primary health care professionals so that they
are well-trained. The main goal is to evaluate the effi-
cacy of an educational intervention to train general
practitioners (GPs) in the right inhalation technique
for the most commonly used inhalers and, afterwards,
to evaluate the improvements in inhalation techniques
performed by their patients. The secondary outcomes
of this intervention will be a clinical control improve-
ment and follow-up of the disease as well as improve-
ment in health-related quality of life. All of these
outcomes have been key goals for more than
10 years.
Study hypothesis
On the basis of current published evidence, inhalation
techniques in patients with COPD are insufficient, and
this overlaps with a lack of well-trained health care pro-
fessionals. Our working hypothesis is that providing an
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educational intervention to primary care professionals
(GPs) will increase by at least by 25 % the number of pa-
tients who report use of the correct inhalation tech-




This study is a pragmatic cluster randomised controlled
trial (Fig. 1). There are various circumstances in which the
pragmatic cluster randomised controlled trial has shown
to be the most appropriate design, particularly when
health programmes are more focused on the organisa-
tional level. This design can also avoid “contamination”
between patients when an educational intervention is ap-
plied in a primary care centre, owing to its having been
individually randomised. This contamination is due to
communication between participants, which can change
the real effect of the intervention. Finally, when educa-
tional strategies for the right patient control are focused
on health care professionals, the only adequate strategy is
the randomised allocation of them [22, 23].
For our trial, the cluster design is based on two levels:
the higher or second level, represented by the GP (who
will receive the educational intervention), and the lower
or first level, represented by the GP’s patients (who have
agreed to participate and will receive the educational
intervention from their GP).
Participants
A total of 267 patients diagnosed with COPD and re-
ceiving inhalation therapy will be selected from 20 gen-
eral practices in 8 primary care centres in Málaga and
Almería, Spain. This sample size is enough to detect a
25 % difference between groups regarding the right per-
formance of inhalation technique, with a power of 80 %
and a confidence level of 95 %. The sample size was ad-
justed according to the standard criteria for cluster ran-
domised trials, using the design effect (DE) of 2.3. The
DE was calculate as follows: DE = 1 + (nc – 1) × ICC
(where nc is the mean number of individuals in the
8 Primary Care Centres
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Fig. 1 Study scheme. COPD chronic obstructive pulmonary disease
Leiva-Fernández et al. Trials  (2016) 17:144 Page 3 of 8
cluster and ICC is the intra-cluster correlation coeffi-
cient). The ICC in the present work was considered to
be 0.1, and the mean cluster size was assumed to be 10
[24–26]. A potential loss of 40 % was estimated. There-
fore, inclusion of 267 patients and 20 GPs will be re-
quired, with all of them signing consent forms to
participate in the study.
First-level participants: patients
Inclusion and exclusion criteria The inclusion criteria
are a COPD diagnosis, being treated at the primary care
centres included in the trial, being prescribed inhalation
therapy and consenting to participate in the trial by
signing the informed consent form. The exclusion cri-
teria are having another respiratory illness not included
in the COPD definition and having cognitive impair-
ments which prevent the individual from completing
the outcome questionnaires or engaging with the edu-
cational intervention.
Recruitment For recruitment, potentially eligible pa-
tients will be identified through a search of practise elec-
tronic records by research assistants. Eligible patients
will receive a brief explanation of the intent of the study
by phone, and, if they are interested, they will be given
an appointment at their primary care centre for a more
detailed explanation. Once the consent form has been
signed, the patient’s inclusion visit will be carried out
and all the variables will be measured (including the
evaluation of the inhalation technique of all inhalers the
patient uses). For eligible patients who decline to partici-
pate, basic information (age, sex, reason for declining)
will be collected from the practice to allow examination
of response bias.
Follow-up The follow-up of patients will be limited to
1 year after the inclusion visit by the research team. Dur-
ing the inclusion visit, all variables will be measured
again, including the evaluation of inhalation techniques.
All measurements will be taken by a research assistant
who has no knowledge of either the randomisation of
the GPs or whether the patients belong to the study or
control arm.
Interventions in patients The patients included in the
intervention group will receive an educational interven-
tion from their GPs, who will train them in the correct
use of their devices. This intervention will consist of the
following:
1. Performance of inhalation techniques to detect
mistakes that will be registered on a specially
designed sheet
2. Demonstration of proper inhalation techniques
3. Identification of mistakes in technique and
opportunities to ask health professionals about how
to perform inhalation properly
The patients will be given an appointment for rein-
forcement visits at 3 and 6 months after the inclusion visit.
In these visits, the GPs will encourage and refresh their
performance of inhalation techniques.
As the educational intervention will not be blinded,
the external researcher responsible for collection of pa-
tient data will not know the patient allocation. The pa-
tients included in the control group will follow the
standard clinical practice.
Second-level participants: GPs
Inclusion and exclusion criteria The inclusion criteria
for second-level participants are that they must be doc-
tors who care for patients included in the COPD Process
of Andalusian Health Service Guidelines (COPD PAI)
[16], use prescribed inhalation therapy and have con-
sented to participate. The exclusion criteria are refusal
to participate in the trial or having to leave the job dur-
ing the trial.
Recruitment and randomisation For the selection of
GPs, the research project will rely on pre-selected pri-
mary care centres. Twenty GPs will be selected by using
a non-probabilistic consecutive sampling method: 10
GPs as the control group and 10 GPs as the study group.
To do that, GPs will be invited to participate and will be
included in either group by using a block randomisation
technique. Each block is formed by four GPs among
whom the two study arms will be uniformly distributed.
Once the blocks have been created, they will be distrib-
uted using a sequence of random numbers and the final
list of GP allocations will be created. The final list of GP
allocations will be guarded by the principal investigator
of the project, and he will inform the allocation of each
GP included in the trial.
The GP’s inclusion visit will be carried out once the ran-
domisation has been done. In this visit, all of the study’s
variables are collected and the inhalation technique of
each inhaler is evaluated through a specific step-by-step
test. This test was specially designed for this study on
basis of the Sociedad Española de Neumología y Cirugía
Torácica (SEPAR) recommendations [4] for most of
the commonly used devices (Spiriva HandiHaler,
Boehringer Ingelheim, Ridgefield, CT, USA; Seretide
Accuhaler, GlaxoSmithKline, Philadelphia, PA, USA;
turbuhalers; pressurized metered-dose inhalers; and
Breezhaler, Novartis, Basel, Switzerland).
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Follow-up Both groups of GPs will be followed up 1 year
after the inclusion visit. In this visit (visit 1), all variables
will be collected once again, and the GPs use of the in-
halation technique will be evaluated.
Interventions in GPs The intervention consists of a
demonstration of correct inhalation technique and the
rationale for it to a group of two to four GPs. After the
demonstration, the participants are asked to identify
their mistakes and ask any questions they may have,
which will be resolved until full understanding of the
technique is achieved. The intervention will take ap-
proximately 15 minutes to deliver. Reinforcement with
written information is provided via the patient’s data col-
lection form (DCF), where the specific step-by-step
schedule for each device is recorded at each patient’s
visit (initial visit and at 3 and 6 months).
Blinding of the intervention for GPs will not be pos-
sible for either researchers or GPs. Table 1 provides a
brief summary of the interventions for the first- and
second-level participants.
Setting
The setting is eight primary care centres in Málaga and
Almería, Spain.
Study variables
Individual variables/first-level variables (patients)
The primary outcome is performance of the correct in-
halation technique by patients (evaluated through a spe-
cific step-by-step test for each inhaler). This test has
been specially designed for this study on the basis of
SEPAR recommendations [4]. We consider the correct
inhalation technique to be used when all steps have been
performed correctly.
Secondary outcomes are functional status as mea-
sured by forced spirometry [27], dyspnoea index as
measured using the Basal Dyspnea Index [28] and the
modified Medical Research Council dyspnoea scale [29]
and health-related quality of life as measured using the
St George’s Respiratory Questionnaire (SGRQ) [30].
Independent variables are age, sex, education level, co-
morbidities, COPD diagnosis duration, mental and/or
cognitive status (Mini Mental State Examination [31]),
types and number of inhalers, previous training received
in use of the inhalation techniques and prescribed treat-
ment for COPD.
Group variables/second-level variables (GPs)
Group and second-level variables are correct performance
of the inhalation techniques by GPs (evaluated using a spe-
cific step-by-step test for each inhaler, described below),
knowledge about COPD and its treatment (evaluated by
using a questionnaire specially designed for this study and
based on COPD PAI [16], Spanish COPD Guidelines [15]
and GOLD guidelines [2]).
Independent variables
The independent variables are age, sex, education level
and access to the COPD clinical practice guidelines.
Statistical analysis
General
A descriptive statistical analysis will be performed for all
study variables. We will calculate the means, medians
and standard deviations for quantitative variables and
the absolute and relative frequencies for qualitative vari-
ables. The 95 % confidence interval will be applied. The
analysis will be done according to the intention-to-treat
principle. The baseline comparison will be made be-
tween the main variables that we expect to be related to
the primary outcome using the χ2 test or analysis of vari-
ance (ANOVA).
At the first level, the between-group comparison for
the primary outcome will be explored using the χ2 test.
Relative risk reduction, absolute risk reduction and NNT
will be calculated. Inferences for secondary outcomes
will be made using ANOVA or the χ2 test.
Finally, a logistic regression model will be used for the
primary outcome (performance of the right inhalation
technique [yes or no]), considering the intervention as
the predictive variable and the rest of the independent
measures as the possible modifying factors. We will use
the usual 5 % significance level (α = 0.05) and the SPSS
version 15.0 statistical software package (SPSS, Chicago,
IL, USA) to run the proposed analysis.
Table 1 Brief summary of interventions in first and second levels
Second level: professionals (GPs) First level: patients
Content Inhalation technique workshop: Inhalation technique workshop:
• Step-by-step correct technique demonstration (how) • Step-by-step correct technique demonstration (how)
• Explanation of each step for each device (why) • Explanation of each step for each device (why)
Who applies the intervention Research team GPs from the intervention group
Who receives the intervention GPs from the intervention group Patients with COPD from the intervention group
COPD chronic obstructive pulmonary disease, GP general practitioner
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Multi-level analysis
ICCs will be determined and published for all primary
outcome variables to assist future research. Potential
confounders will be compared between groups to con-
firm that the randomisation has provided the appropri-
ate balance.
The effect of the intervention on outcomes measured
on a continuous scale (such as SGRQ score) will be esti-
mated and tested using mixed model ANOVA in which
time and treatment group will be fixed effects and GP
and subject will be random effects. The effect of the
intervention on the dichotomous variables will be ana-
lysed using generalised estimating equations with a lo-
gistic link and a model structure that is analogous to
that described above.
Study limitations
The first limitation is about the actual study design. In
pragmatic cluster randomised controlled trials, the first
bias to take into account is the selection bias, as the ran-
domisation is usually applied in the second level, before
recruitment of the first-level participants, which is where
the intervention impact is measured. However, there are
strategies that minimise this bias, and we are using these
in this study. First, the selection and follow-up of pa-
tients (patient inclusion visit and visit 1) will be carried
out by an external researcher who will have no know-
ledge of GP randomisation. Second, the effect of the
intervention over recruitment can lead to different re-
cruitment indexes, depending on the groups, due to the
possibility that GPs in the control group could be less
motivated to participate. Moreover, to avoid different re-
cruitment indexes in both groups, once the trial is fin-
ished, the GPs in the control group will be trained in the
same way as the study group professionals were trained
(if the intervention shows a significant improvement in
patients) [23, 32].
Another study limitation is the potential for loss to
follow-up. To minimise these losses, patients will be
contacted at least three different times and at different
times of day. However, loss to follow-up was taken into
account in the sample size calculation and will be taken
into account in performing data analysis (intention-to-
treat analysis).
Another bias is the Hawthorne effect, which relates to
how participants in a study change their behaviour
under observation. However, we believe that the effect of
this bias will be minimal because of patients’ being
trained and followed by their GPs, with the exception of
the inclusion and final visits. Besides, there is a control
group in which the follow-up will permit us to minimise
the real impact of this bias.
There could be measurement bias due to mistakes in
recording of some variables or interviewer bias due to
the administration of the questionnaires. To minimise
these biases, interviewers will have been trained previ-
ously to ensure that visits will be as homogeneous as
possible. A DCF and a manual that explains how each
variable is measured at the follow-up visits will be given
to the GPs in the intervention group.
Finally, we point out that a rescue mechanism is con-
templated for the control group. This mechanism will be
applied when the patients perform critical errors in the
inhalation techniques that compromise the totality of
the drug deposition and its effect. This rescue mechan-
ism can create an information bias which could change
the effect of the educational intervention in this study.
However, we must ensure the well-being of the patient.
All adverse events will be reported on the DCF and will
be taken into account in the post hoc analysis.
Ethics
This study has been approved by the local ethics com-
mittee of Malaga (CEI Provincial de Malaga; 12/12/13).
Patients and GPs will sign informed consent forms.
Discussion
In the last 20 years, multiple studies have been carried
out showing that health care professionals prescribe in-
halers without adequate knowledge about their use.
Current guidelines on treating COPD recommend that
physicians demonstrate to patients how to use the differ-
ent devices at their first appointment, and then to cor-
rect improper use at follow-up visits [1, 2]. However,
this approach is not widely applied in routine clinical
practice, as shown by the high percentage of health care
professionals who are incapable of simply demonstrating
the correct use of the inhaler devices [10, 20]. This lack
of knowledge has not improved recently, despite efforts
by health care education institutions [20].
It is widely accepted that poor disease control among
patients with COPD is due to improper use of inhalation
medicines [8]. The inhalation device may affect inhaler
technique because there are a wide range of inhaler de-
vices, some of which are easier to use than others [17, 19].
So, these potentially confounding factors will be consid-
ered in our strategy of statistical analysis.
Mishandling of inhalation devices decreases patient
adherence to the inhaler therapeutic regimen, comprom-
ising treatment efficacy [7]. If the proposed educational
intervention is effective, it stands a good chance of being
implementable, owing to its simplicity. It could be
exported to any health care field for inpatients and out-
patients, both nationally and internationally, with adap-
tation for the most commonly used inhalers in each
area. Previously conducted clinical trials by our research
group have shown that a simple educational intervention
is altogether more effective in teaching patients with
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COPD about the right management of their inhalers.
This proposed clinical trial will verify and confirm our
previous proof-of-concept work which indicated that a
simple educational intervention delivered by GPs in pri-
mary care can improve inhaler technique among pa-
tients with COPD. This would provide high-quality
evidence about educational interventions with primary
health care professionals to improve the management of
inhaler treatment, the clinical outcomes and health-
related quality of life of patients with COPD, all of which
are key aims in any assistance process. These factors have
high importance in primary care, where most patients
with COPD are treated with this kind of technique.
In addition to patient benefit related to implementation
of the inhalation technique intervention (better treatment
adherence, improvement in clinical status and health out-
comes), we expect the intervention to be cost-effective,
too, with reduction in the direct and indirect costs associ-
ated with the management of COPD. This will have a
positive impact in organisations, resource management,
health care services and health politics, and overall in the
health and well-being of patients with COPD.
Trial status
We have divided the participant recruitment into two
phases and are recruiting GPs and patients for the sec-
ond phase of the study.
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